

Supporting Information

Supplementary methods and results

This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix to: Shawon MSR, Yu J, Sedrakyan A, et al. Non-index hospital re-admissions after hospitalisation with acute myocardial infarction and geographic remoteness, New South Wales, 2005–2020: a retrospective cohort study. *Med J Aust* 2024; doi: 10.5694/mja2.52420.

Supplementary methods

Table 1. Medical condition and procedure codes for index hospital admissions with acute myocardial infarction

Variable	Description		
Procedures	Australian Classification of Health Interventions (ACHI) codes ¹		
Percutaneous coronary	38300-00, 38303-00, 38306-00, 38306-01, 38306-02, 38309-00, 38312-00, 38312-01,		
interventions (PCI)	38315-00, 38318-00, 38318-01, 90218-00, 90218-01, 90218-02, 90218-03		
Coronary artery bypass	38497-00, 38497-01, 38497-02, 38497-03, 38497-04, 38497-05, 38497-06, 38497-07,		
grafting (CABG)	38500-00, 38500-01, 38500-02, 38500-03, 38500-04, 38500-05, 38503-00, 38503-01,		
	38503-02, 38503-03, 38503-04, 38503-05, 90201-00, 90201-01, 90201-02, 90201-03		
Medical conditions	International Statistical Classification of Diseases and Related Health Problems, 10th		
	Revision, Australian Modification (ICD-10-AM) codes and definitions ^{1,2}		
Myocardial infarction	I21 as a principal diagnosis at index admission		
	Classification of acute myocardial infarction type:		
	• ST-elevated myocardial infarction – STEMI: I21.0–I21.3 ¹		
	 Non–ST-elevated myocardial infarction – NSTEMI I21.4¹ 		
	Unspecified myocardial infarction: I21.91		
Diabetes	E10, E11, E12, E13, E14		
Hypertension	I10, U82.3, I11, I12, I13, I15		
Chronic obstructive	J43, J44, U83.2		
pulmonary disease			
Congestive heart failure	I43, I50, I09.9, I11.0, I13.0, I13.2, I42.0, I42.5, I42.6, I42.7, I42.8, I42.9, P29.0, U82.2		
Chronic kidney disease	N18, U87.1		
Cardiomyopathy	I42		
Coronary artery disease	I20, I21, I22, I24, I25, U82.1		
Sleep apnoea	G47.3		
Obesity	E66, U78.1		
Stroke	G45, G46, H34.0, I60, I61, I62, I63, I64, I65, I66, I67, I68, I69		
Peripheral vascular disease	I70, I71, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8, Z95.9, U82.2		
Atrial fibrillation	I48		

Table 2. Hospital peer groups

Peer group	Description
Principal referral	Greater than 35,000 acute weighted separations AND offering highly specialised services (such as
	bone marrow and other specialised transplants, severe burn injury, major trauma)
Major hospitals	35,000 or less but greater than 10,000-17,000 acute weighted separations
	Also considers the availability of one or more specialist services requiring specific infrastructure
	(such as cardiac catheterisation, comprehensive cancer centre, in-centre dialysis and medical
	radiation imaging) OR average acute National Weighted Activity Unit per separation
District group	4,000-10,000 or less but greater than 2,000 acute separations
Community hospitals	2,000 or less acute separations.
	Also considers total separations and percentual surgery
Other peer groups	Paediatric specialist, Ungrouped acute, Psychiatric, Nursing home, Multi-purpose service, Sub-
	acute, Palliative care, Rehabilitation, Mothercraft, Other ungrouped, Dialysis services

Source: Adapted from reference 3.

References

- 1. Australian Institute of Health and Welfare. Better Cardiac Care measures for Aboriginal and Torres Strait Islander people: sixth national report 2021. 30 Nov 2021. https://www.aihw.gov.au/reports/indigenous-australians/better-cardiac-care-measures-2021/summary (viewed Aug 2024).
- $2.\ Independent\ Health\ and\ Aged\ Care\ Pricing\ Authority Supplementary\ codes\ for\ chronic\ conditions\ (ACS\ 0003).$ https://www.ihacpa.gov.au/sites/default/files/2022-
- 01/ACS% 200003% 20Supplementary% 20Codes% 20for% 20Chronic% 20Conditions.pdf (viewed Sep 2023).
- 3. NSW Health. NSW Hospital Peer Groups 2016. https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/IB2016_013.pdf (viewed Aug 2024).

Supplementary results

 $Table \ 3. \ Selected \ characteristics \ of \ people \ with \ myocardial \ infarction \ (2005\text{-}2020), \ overall \ and \ by \ remoteness \ category$

Characteristic	All areas	Major cities	Regional or remote areas
Acute myocardial infarction admissions	182330	123859 (67.9%)	58471 (32.1%)
Type of acute myocardial infarction			
ST-elevation myocardial infarction	54525 (29.9%)	37716 (30.5%)	16809 (28.7%)
Non-ST-elevation myocardial infarction	117578 (64.5%)	80732 (65.2%)	36846 (63.0%)
Non-specific myocardial infarction	10227 (5.6%)	5411 (4.4%)	4816 (8.2%)
Coronary revascularisation			
Percutaneous Coronary Intervention	48463 (26.6%)	37755 (30.5%)	10708 (18.3%)
Coronary Artery Bypass Graft	14029 (7.7%)	10026 (8.1%)	4003 (6.8%)
Emergency admission	128765 (70.6%)	87565 (70.7%)	41200 (70.5%)
Had inter-hospital transfer	68891 (37.8%)	42056 (34.0%)	26835 (45.9%)
Length of stay (days), median (IQR)	5 (3–9)	5 (3–9)	5 (2–9)
Patient age, years mean (SD)	70.3 (14.2)	70.0 (14.4)	71.1 (13.9)
Sex (women)	64600 (35.4%)	43132 (34.8%)	21468 (36.7%)
Index of Relative Socio-economic	, , ,		
Disadvantage			
Q1 - most disadvantaged	48429 (26.6%)	27524 (22.2%)	20905 (35.8%)
Q2	38520 (21.1%)	19087 (15.4%)	19433 (33.2%)
Q3	36245 (19.9%)	23997 (19.4%)	12248 (20.9%)
04	28834 (15.8%)	23320 (18.8%)	5514 (9.4%)
Q5 - least disadvantaged	30273 (16.6%)	29905 (24.1%)	368 (0.6%)
Private insurance	54959 (30.1%)	40191 (32.4%)	14768 (25.3%)
Comorbidity profile	01303 (001270)	10191 (01117)	11700 (201071)
Diabetes	52434 (28.8%)	36670 (29.6%)	15764 (27.0%)
Congestive heart failure	44348 (24.3%)	30208 (24.4%)	14140 (24.2%)
Cardiac arrhythmias	62656 (34.4%)	43271 (34.9%)	19385 (33.2%)
Pulmonary circulation disorders	6799 (3.7%)	4651 (3.8%)	2148 (3.7%)
Peripheral vascular disease	12117 (6.6%)	7711 (6.2%)	4406 (7.5%)
Renal failure	27360 (15.0%)	18994 (15.3%)	8366 (14.3%)
Liver disease	3474 (1.9%)	2469 (2.0%)	1005 (1.7%)
Metastatic cancer	2615 (1.4%)	1748 (1.4%)	867 (1.5%)
Solid tumour, no metastasis	7455 (4.1%)	4936 (4.0%)	2519 (4.3%)
Cardiogenic shock	5671 (3.1%)	4205 (3.4%)	1466 (2.5%)
Index hospital funding type	0071 (81170)	1200 (01170)	1.00 (2.070)
Public	155160 (85.1%)	103034 (83.2%)	52126 (89.1%)
Private	27170 (14.9%)	20825 (16.8%)	6345 (10.9%)
Index hospital category	2/1/0 (11.5/0)	20020 (10.070)	03 13 (10.570)
Principal referral	88668 (48.6%)	76604 (61.8%)	12064 (20.6%)
Large public	41691 (22.9%)	18532 (15.0%)	23159 (39.6%)
Other public	24045 (13.2%)	7190 (5.8%)	16855 (28.8%)
Private	27170 (14.9%)	20825 (16.8%)	6345 (10.9%)
In-hospital mortality	14233 (7.8%)	9432 (7.6%)	4801 (8.2%)
30-day readmission	28309 (16.8%)	18673 (16.3%)	9636 (18.0%)

CI = confidence interval; SD = standard deviation.


 $Table \ 4. \ Selected \ characteristics \ of people \ re-admitted \ within \ 30 \ days \ of \ index \ hospitalisation \ with \ acute \ myocardial \ infarction \ (2005-2020), \ overall \ and \ by \ remoteness \ category$

Characteristic Index re-admission Index re-admission Characteristics of index acute myocardial infarction stay		Regional/ren		Major	
30-day re-admissions	Non-index re-				
Characteristics of index acute myocardial infarction stay Type of acute myocardial infarction 2766 (24.0%) 1999 (27.9%) 999 (20.8%) ST-elevation-myocardial infarction 2766 (24.0%) 1999 (27.9%) 999 (20.8%) Non-ST-elevation myocardial infarction 263 (2.3%) 225 (3.1%) 421 (8.8%) Coronary revascularisation 263 (2.3%) 225 (3.1%) 421 (8.8%) Coronary revascularisation Percutaneous Coronary Intervention 2806 (24.4%) 1872 (26.2%) 453 (9.4%) Coronary Artery Bypass Graft 608 (5.3%) 790 (11.0%) 121 (2.5%) Emergency admission 10147 (88.1%) 3735 (52.2%) 4013 (83.5%) Had inter-hospital transfer 1840 (16.0%) 4032 (56.4%) 1100 (22.9%) Length of stay (days), median (IQR) 5 (3-9) 6 (3-14) 5 (3-9) 6 (3-14) 75.7 (13.0) Sex (women) 4586 (39.8%) 2638 (36.9%) 2047 (42.6%) Index of Relative Socio-economic Disadvantage Q1 - most disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Charles of the medical conditions Diabetes 4183 (36.3%) 2464 (34.4%) 1557 (32.4%) Congets where the failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Private insurance 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 336 (5.0%) 3287 (6.0%) 71 (1.5%) Dishergin hospital funding type Public 11083 (96.2%) 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (10.0%) Discharging hospital funding type Public 11083 (96.2%) 5274 (13.0%) 200 (4.2%) 2399 (20.8%) 927 (13.0%) 2364 (49.2%) 2399 (20.8%) 927 (13.0%) 2364 (49.2%) 2399 (20.8%) 927 (13.0%) 2364 (49.2%) 2399 (20.8%) 927 (13.0%) 2364 (49.2%) 2399 (20.8%) 927	admission				
Type of acute myocardial infarction ST-elevation-myocardial infarction ST-elevation-myocardial infarction ST-elevation myocardial infarction ST-elevation S	4832 (50.1%)	4804 (49.9%)	7154 (38.3%)	11519 (61.7%)	
Type of acute myocardial infarction ST-elevation-myocardial infarction ST-elevation myocardial infarction Non-ST-elevation myocardial infarction Non-specific myocardial infarction Non-specific myocardial infarction ST-elevation myocardial infarction Non-specific myocardial infarction Percutaneous Coronary Intervention Percutaneous Coronary Intervention Percutaneous Coronary Intervention State of					
Infarction 2766 (24.0%) 1999 (27.9%) 999 (20.8%)					
ST-elevation-myocardial infarction 2766 (24.0%) 1999 (27.9%) 999 (20.8%) Non-ST-elevation myocardial infarction 8490 (73.7%) 4930 (68.9%) 3384 (70.4%) Non-specific myocardial infarction 263 (2.3%) 225 (3.1%) 421 (8.8%) Coronary revascularisation 263 (2.3%) 225 (3.1%) 421 (8.8%) Record of the product o					
Infarction 2766 (24.0%) 1999 (27.9%) 999 (20.8%)					
Non-ST-elevation myocardial infarction	1454 (30.1%)	000 (20 80/)	1000 (27 00/)	2766 (24.00/.)	
infarction 8490 (73.7%) 4930 (68.9%) 3384 (70.4%) Non-specific myocardial infarction 263 (2.3%) 225 (3.1%) 421 (8.8%) Coronary revascularisation Percutaneous Coronary Intervention 2806 (24.4%) 1872 (26.2%) 453 (9.4%) Coronary Artery Bypass Graft 608 (5.3%) 790 (11.0%) 121 (2.5%) Emergency admission 10147 (88.1%) 3735 (52.2%) 4013 (83.5%) Had inter-hospital transfer 1840 (16.0%) 4032 (56.4%) 1100 (22.9%) Length of stay (days), median (1QR) 5 (3-9) 6 (3-14) 5 (3-9) Age (years), mean (SD) 73.5 (14.1) 71.1 (14.1) 75.7 (13.0) Sex (women) 4586 (39.8%) 2638 (36.9%) 2047 (42.6%) Index of Relative Socio-economic Disadvantage 1914 (26.8%) 1833 (38.2%) Q1 - most disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%)	1434 (30.1%)	999 (20.6%)	1999 (27.9%)	2700 (24.0%)	
Non-specific myocardial infarction 263 (2.3%) 225 (3.1%) 421 (8.8%)	3110 (64.4%)	3384 (70.4%)	4930 (68 9%)	8490 (73.7%)	
infarction 263 (2.3%) 225 (3.1%) 421 (8.8%) Coronary revascularisation Percutaneous Coronary Intervention 2806 (24.4%) 1872 (26.2%) 453 (9.4%) Coronary Artery Bypass Graft 608 (5.3%) 790 (11.0%) 121 (2.5%) Emergency admission 10147 (88.1%) 3735 (52.2%) 4013 (83.5%) Had inter-hospital transfer 1840 (16.0%) 4032 (56.4%) 1100 (22.9%) Length of stay (days), median (IQR) 5 (3–9) 6 (3–14) 5 (3–9) Age (years), mean (SD) 73.5 (14.1) 71.1 (14.1) 75.7 (13.0) Sex (women) 4586 (39.8%) 2638 (36.9%) 2047 (42.6%) Index of Relative Socio-economic Disadvantage 01 most disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance	3110 (04.470)	3304 (70.470)	4730 (00.770)	0490 (73.170)	
Coronary revascularisation	268 (5.5%)	421 (8.8%)	225 (3.1%)	263 (2.3%)	
Percutaneous Coronary Intervention 2806 (24.4%) 1872 (26.2%) 453 (9.4%) 121 (2.5%) Emergency admission 10147 (88.1%) 3735 (52.2%) 4013 (83.5%) 4010 (22.9%) 4010 (200 (0.070)	121 (0.070)	(0.17,1)	200 (20070)	
Intervention					
Emergency admission 10147 (88.1%) 3735 (52.2%) 4013 (83.5%) Had inter-hospital transfer 1840 (16.0%) 4032 (56.4%) 1100 (22.9%) Length of stay (days), median (IQR) 5 (3-9) 6 (3-14) 5 (3-9) Age (years), mean (SD) 73.5 (14.1) 71.1 (14.1) 75.7 (13.0) Sex (women) 4586 (39.8%) 2638 (36.9%) 2047 (42.6%) Index of Relative Socio-economic Disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 0 2514 (35.1%) 1557 (32.4%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%)	972 (20.1%)	453 (9.4%)	1872 (26.2%)	2806 (24.4%)	
Had inter-hospital transfer 1840 (16.0%) 4032 (56.4%) 1100 (22.9%) Length of stay (days), median (IQR) 5 (3–9) 6 (3–14) 75.7 (13.0) Age (years), mean (SD) 73.5 (14.1) 71.1 (14.1) 75.7 (13.0) Sex (women) 4586 (39.8%) 2638 (36.9%) 2047 (42.6%) Index of Relative Socio-economic Disadvantage Q1 - most disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2	480 (9.9%)	121 (2.5%)	790 (11.0%)	608 (5.3%)	
Length of stay (days), median (IQR) 5 (3-9) 6 (3-14) 5 (3-9) Age (years), mean (SD) 73.5 (14.1) 71.1 (14.1) 75.7 (13.0) Sex (women) 4586 (39.8%) 2638 (36.9%) 2047 (42.6%) Index of Relative Socio-economic Disadvantage 1914 (26.8%) 1833 (38.2%) Q1 - most disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 4183 (36.3%) 2464 (34.4%) 1557 (32.4%) Oilbetes 4183 (36.3%) 2464 (34.4%) 1557 (32.4%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders	3048 (63.1%)	4013 (83.5%)	3735 (52.2%)	10147 (88.1%)	Emergency admission
(IQR) 5 (3-9) 6 (3-14) 5 (3-9) Age (years), mean (SD) 73.5 (14.1) 71.1 (14.1) 75.7 (13.0) Sex (women) 4586 (39.8%) 2638 (36.9%) 2047 (42.6%) Index of Relative Socio-economic Disadvantage 201 most disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 0ther medical conditions 1557 (32.4%) Diabetes 4183 (36.3%) 2464 (34.4%) 1557 (32.4%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascul	3109 (64.3%)	1100 (22.9%)	4032 (56.4%)	1840 (16.0%)	Had inter-hospital transfer
Age (years), mean (SD) 73.5 (14.1) 71.1 (14.1) 75.7 (13.0) Sex (women) 4586 (39.8%) 2638 (36.9%) 2047 (42.6%) Index of Relative Socio-economic Disadvantage 2638 (33.1%) 1914 (26.8%) 1833 (38.2%) Q1 - most disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 0 2514 (35.1%) 1557 (32.4%) Other medical conditions 0 <td></td> <td></td> <td></td> <td></td> <td></td>					
Sex (women) 4586 (39.8%) 2638 (36.9%) 2047 (42.6%) Index of Relative Socio-economic Disadvantage 8 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q1 - most disadvantaged 2663 (23.1%) 1934 (16.8%) 1031 (14.4%) 1630 (33.9%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 0 2514 (35.1%) 877 (18.3%) Other medical conditions 0 2514 (35.1%) 877 (18.3%) Other medical conditions 0 2514 (35.1%) 1557 (32.4%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) <td>5 (3–12)</td> <td></td> <td></td> <td></td> <td></td>	5 (3–12)				
Index of Relative Socio-economic Disadvantage Q1 - most disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions	68.9 (13.6)				
Disadvantage Q1 - most disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 0 2514 (35.1%) 877 (18.3%) Diabetes 4183 (36.3%) 2464 (34.4%) 1557 (32.4%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer	1694 (35.1%)	2047 (42.6%)	2638 (36.9%)	4586 (39.8%)	
Q1 - most disadvantaged 2663 (23.1%) 1914 (26.8%) 1833 (38.2%) Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 0 2544 (34.4%) 1557 (32.4%) Ocongestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 2					
Q2 1938 (16.8%) 1031 (14.4%) 1630 (33.9%) Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 0 2464 (34.4%) 1557 (32.4%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%)					
Q3 2504 (21.7%) 1327 (18.5%) 920 (19.2%) Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 0 2514 (35.1%) 877 (18.3%) Diabetes 4183 (36.3%) 2464 (34.4%) 1557 (32.4%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiagenic shock 315 (2.7%) </td <td>1852 (38.3%)</td> <td></td> <td></td> <td></td> <td></td>	1852 (38.3%)				
Q4 2134 (18.5%) 1272 (17.8%) 408 (8.5%) Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 000 2514 (35.1%) 877 (18.3%) Diabetes 4183 (36.3%) 2464 (34.4%) 1557 (32.4%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type <td>1567 (32.4%)</td> <td></td> <td></td> <td></td> <td></td>	1567 (32.4%)				
Q5 - least disadvantaged 2275 (19.7%) 1609 (22.5%) 13 (0.3%) Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions 000	1010 (20.9%)				
Private insurance 2309 (20.0%) 2514 (35.1%) 877 (18.3%) Other medical conditions Diabetes 4183 (36.3%) 2464 (34.4%) 1557 (32.4%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type 436 (3.8%) 1920 (26.8%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category 200 (4.2%) Principal referral	372 (7.7%)				
Other medical conditions 4183 (36.3%) 2464 (34.4%) 1557 (32.4%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type 436 (3.8%) 1920 (26.8%) 46 (1.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category 201 (2.8%) 201 (4.2%) Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public	31 (0.6%)				
Diabetes 4183 (36.3%) 2464 (34.4%) 1557 (32.4%) Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type 11083 (96.2%) 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category 201 (2.8%) 200 (4.2%) Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8	1161 (24.0%)	8//(18.5%)	2514 (55.1%)	2309 (20.0%)	
Congestive heart failure 4059 (35.2%) 2273 (31.8%) 1643 (34.2%) Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type 11083 (96.2%) 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category 201 (2.8%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	1452 (30.0%)	1557 (22 40/)	2464 (24 40/.)	/192 (26 20/.)	
Cardiac arrhythmias 4845 (42.1%) 2888 (40.4%) 1818 (37.8%) Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type 11083 (96.2%) 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	1235 (25.6%)				
Pulmonary circulation disorders 649 (5.6%) 364 (5.1%) 271 (5.6%) Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type 11083 (96.2%) 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	1711 (35.4%)				
Peripheral vascular disease 944 (8.2%) 621 (8.7%) 484 (10.1%) Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type 11083 (96.2%) 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	216 (4.5%)				<u> </u>
Renal failure 2795 (24.3%) 1484 (20.7%) 997 (20.8%) Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type Public 11083 (96.2%) 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	417 (8.6%)				
Liver disease 290 (2.5%) 173 (2.4%) 95 (2.0%) Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type 11083 (96.2%) 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	774 (16.0%)			` ′	1
Metastatic cancer 276 (2.4%) 118 (1.6%) 116 (2.4%) Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type 11083 (96.2%) 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	103 (2.1%)				
Solid tumour, no metastasis 617 (5.4%) 356 (5.0%) 287 (6.0%) Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type 201 (2.8%) 47 (1.5%) Public 11083 (96.2%) 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category 200 (4.2%) Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	76 (1.6%)				
Cardiogenic shock 315 (2.7%) 201 (2.8%) 71 (1.5%) Discharging hospital funding type	241 (5.0%)				
Discharging hospital funding type 5234 (73.2%) 4758 (99.0%) Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	88 (1.8%)				
Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	` `	Ì	, ,) í	
Private 436 (3.8%) 1920 (26.8%) 46 (1.0%) Discharging hospital category Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	4092 (84.7%)	4758 (99.0%)	5234 (73.2%)	11083 (96.2%)	
Discharging hospital category 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)	740 (15.3%)	1		· · · · · · · · · · · · · · · · · · ·	Private
Principal referral 8001 (69.5%) 3543 (49.5%) 200 (4.2%) Large public 2399 (20.8%) 927 (13.0%) 2364 (49.2%)					Discharging hospital category
	1452 (30.0%)				Principal referral
0411:-	1577 (32.6%)				<u>U 1</u>
	1056 (21.9%)	2192 (45.6%)	728 (10.2%)	611 (5.3%)	Other public
Private 436 (3.8%) 1920 (26.8%) 46 (1.0%)	740 (15.3%)	46 (1.0%)	1920 (26.8%)	436 (3.8%)	
30-day re-admission parameters				T	30-day re-admission parameters
Length of stay (days), median	2 (1.7)	4.(1.0)	4.41.00	4.41.00	
(IQR) 4 (1-8) 4 (1-8) 4 (1-8)	3 (1–7)				
30-day mortality 1304 (11.3%) 659 (9.2%) 670 (13.9%) 1-year mortality 3457 (30.0%) 1670 (23.3%) 1601 (33.3%)	368 (7.6%) 974 (20.2%)				

IQR = interquartile range; SD = standard deviation.


The discharging hospital during index hospitalisation was considered as the index hospital.

Figure 1. Love plot of standardised differences in covariates between patients with and without care fragmentation before and after propensity score matching in all people with myocardial infarction




MI = myocardial infarction; NSTEMI = non-ST-elevated myocardial infarction; SES = socio-economic status (Index of Relative Socio-economic Disadvantage)

Figure 2. Love plot of standardised differences in covariates between patients with and without care fragmentation before and after propensity score matching in people with myocardial infarction in major cities



MI = myocardial infarction; NSTEMI = non-ST-elevated myocardial infarction; SES = socio-economic status (Index of Relative Socio-economic Disadvantage)

Figure 3. Love plot of standardised differences in covariates between patients with and without care fragmentation before and after propensity score matching in people with myocardial infarction in regional/remote areas



MI = myocardial infarction; NSTEMI = non-ST-elevated myocardial infarction; SES = socio-economic status (Index of Relative Socio-economic Disadvantage)

Table 5. Non-index hospital re-admissions within 30 days of hospitalisation with acute myocardial infarction, overall: multivariate analyses*

Variables	Adjusted odds ratio (95% CI)	
Age at myocardial infarction admission		
<65 years	1	
65-74 years	0.86 (0.81-0.92)	
75+ years	0.59 (0.55-0.62)	
Sex (women)	0.92 (0.87-0.96)	
Socio-economic status (IRSD)		
Q1 - most disadvantaged	1.16 (1.07-1.25)	
Q2	1.00 (0.92-1.09)	
Q3	0.94 (0.86-1.02)	
Q4	0.90 (0.82-0.98)	
Q5 - least disadvantaged	1	
Residence		
Major cities	1	
Regional/remote areas	1.61 (1.53-1.70)	
Private insurance	1.84 (1.74-1.95)	
Other conditions		
Diabetes	0.92 (0.88-0.97)	
Congestive heart failure	0.90 (0.85-0.96)	
Cardiac arrhythmias	1.03 (0.98-1.09)	
Pulmonary circulation disorders	0.98 (0.88-1.09)	
Peripheral vascular disease	1.12 (1.03-1.22)	
Renal failure	0.90 (0.84-0.96)	
Liver disease	0.89 (0.76-1.04)	
Metastatic cancer	0.63 (0.51-0.77)	
Solid tumour, no metastasis	1.12 (0.98-1.27)	
Cardiogenic shock	1.04 (0.88-1.21)	
Myocardial infarction type		
STEMI	1	
NSTEMI	0.84 (0.79-0.89)	
Non-specific MI	0.89 (0.78-1.01)	
Emergency admission	2.29 (2.21-2.37)	
Revascularisation procedure	1.40 (1.33-1.48)	
Had transfer	6.83 (6.46-7.21)	
Hospital type		
Public	1	
Private	10.2 (9.21-11.3)	

 $[\]ensuremath{^{*}}$ Adjusted for age, sex, and other medical conditions.